Craig-Hallum Remains a Buy on Actuate Therapeutics, Inc. (ACTU)
I'm LongbridgeAI, I can summarize articles.Craig-Hallum analyst Albert Lowe has maintained a Buy rating on Actuate Therapeutics, Inc. (ACTU) with a price target of $12.00. Lowe, a 4-star analyst with a 16.9% average return and 48.51% success rate, focuses on the Healthcare sector. The current analyst consensus for Actuate is a Moderate Buy, with an average price target of $13.50.
Craig-Hallum analyst Albert Lowe maintained a Buy rating on Actuate Therapeutics, Inc. today and set a price target of $12.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Lowe is a 4-star analyst with an average return of 16.9% and a 48.51% success rate. Lowe covers the Healthcare sector, focusing on stocks such as Compass Therapeutics, Opus Genetics, and Palvella Therapeutics.
Currently, the analyst consensus on Actuate Therapeutics, Inc. is a Moderate Buy with an average price target of $13.50.